GlassScriptPhysician profile
Rebecca M Sugg
NPI 1982656773
$4,618.02
in general payments reported to CMS, 2019-2025
44 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $831 · 2021: $347 · 2022: $508 · 2023: $344 · 2024: $513 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $656.55 | 2019 | |
| Microvention, INC. | $606.39 | 2020 | |
| Medtronic, INC. | $532.69 | 2021-2025 | Pipeline, Solitaire X |
| Ucb, INC. | $329.06 | 2019-2025 | Nayzilam, Zilbrysq, Briviact |
| Sk Life Science, INC. | $254.55 | 2021-2025 | |
| Stryker Corporation | $245.06 | 2020-2025 | Trevo, Surpass Evolve, Neuroform Atlas |
| Alexion Pharmaceuticals, INC. | $225.79 | 2021-2024 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $220.91 | 2019-2021 | |
| Csl Behring | $188.88 | 2024-2025 | Kcentra |
| Eisai INC. | $138.34 | 2021-2024 | |
| Amgen INC. | $137.88 | 2020-2025 | Uplizna |
| Penumbra, INC. | $126.99 | 2025 | Penumbra Coil 400 |
| Acadia Pharmaceuticals INC | $81.13 | 2022-2025 | Nuplazid, Daybue |
| Biogen, INC. | $71.39 | 2022-2025 | Skyclarys |
| Jazz Pharmaceuticals INC. | $56.42 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Sugg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.